Biomaterial Database

[Assessment of the therapeutic effect of Trental 400. Double-blind study in geriatric patients with circulatory disorders]. 1977

G Feine-Haake

A double blind trial was performed in a geriatric unit in order to evaluate efficacy and tolerability of Trental 400 (400 mg Pentoxifylline per tablet) against a comparative formulation (2,4 mg adenosine per tablet) in 36 patients displaying signs of peripheral vascular disease and in 16 patients with symptoms of cerebrovascular disorders. 3 tablets were administered daily over a period of three months. Trental 400 proved to be significantly more effective in either indication group. Based on the observed good tolerability and pronounced efficacy Trental 400 can be considered as an easy to handle therapeutic tool for the long term treatment of symptoms resulting from peripheral and cerebral vascular disorders.

UI	MeSH Term	Description	Entries
D008134	Long-Term Care	Care over an extended period, usually for a chronic condition or disability, requiring periodic, intermittent, or continuous care.	Care, Long-Term,Long Term Care
D008875	Middle Aged	An adult aged 45 - 64 years.	Middle Age
D010431	Pentoxifylline	A METHYLXANTHINE derivative that inhibits phosphodiesterase and affects blood rheology. It improves blood flow by increasing erythrocyte and leukocyte flexibility. It also inhibits platelet aggregation. Pentoxifylline modulates immunologic activity by stimulating cytokine production.	Agapurin,BL-191,Oxpentifylline,Pentoxil,Torental,Trental,BL 191,BL191
D001775	Blood Circulation	The movement of the BLOOD as it is pumped through the CARDIOVASCULAR SYSTEM.	Blood Flow,Circulation, Blood,Blood Flows,Flow, Blood
D002537	Intracranial Arteriosclerosis	Vascular diseases characterized by thickening and hardening of the walls of ARTERIES inside the SKULL. There are three subtypes: (1) atherosclerosis with fatty deposits in the ARTERIAL INTIMA; (2) Monckeberg's sclerosis with calcium deposits in the media and (3) arteriolosclerosis involving the small caliber arteries. Clinical signs include HEADACHE; CONFUSION; transient blindness (AMAUROSIS FUGAX); speech impairment; and HEMIPARESIS.	Cerebral Arteriosclerosis,Intracranial Atherosclerosis,Cerebral Atherosclerosis,Arterioscleroses, Cerebral,Arterioscleroses, Intracranial,Arteriosclerosis, Cerebral,Arteriosclerosis, Intracranial,Atheroscleroses, Cerebral,Atheroscleroses, Intracranial,Atherosclerosis, Cerebral,Atherosclerosis, Intracranial,Cerebral Arterioscleroses,Cerebral Atheroscleroses,Intracranial Arterioscleroses,Intracranial Atheroscleroses
D005121	Extremities	The farthest or outermost projections of the body, such as the HAND and FOOT.	Limbs,Extremity,Limb
D005260	Female		Females
D006801	Humans	Members of the species Homo sapiens.	Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368	Aged	A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available.	Elderly
D013805	Theobromine	3,7-Dimethylxanthine. The principle alkaloid in Theobroma cacao (the cacao bean) and other plants. A xanthine alkaloid that is used as a bronchodilator and as a vasodilator. It has a weaker diuretic activity than THEOPHYLLINE and is also a less powerful stimulant of smooth muscle. It has practically no stimulant effect on the central nervous system. It was formerly used as a diuretic and in the treatment of angina pectoris and hypertension. (From Martindale, The Extra Pharmacopoeia, 30th ed, pp1318-9)